Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009502 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01009502: Clinical Trial Phase 1 study, sponsored by Northwestern University.
NCT01009502 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01009502, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This was originally designed as a phase I/II trial studying the side effects of sodium stibogluconate and how well it works in treating patients with myelodysplastic syndromes. Unfortunately, due to funding issues, the phase II portion was never conducted.
Primary Outcome
To determine the effect of SSG treatment on clinical parameters of MDS. This will include determination of cytopenias, bone marrow dysplasia, % myeloid blasts, transfusion frequency, incidence of infection and phagocyte function in MDS subjects pre and during treatment. Serum Sb levels will also be determined as an early indication of toxicity.
Interventions
- DRUG sodium stibogluconate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Why NCT01009502 stopped before completion
NCT01009502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which sodium stibogluconate is the first listed.
NCT01009502 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01009502 about?
NCT01009502 is a clinical study titled "Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome". Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This was originally designed as a phase I/II trial studying the side effects of sodium stibogluconate and how well it works in treating patients with myelodysplastic syndromes. Unfortun...
What is the current status of trial NCT01009502?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2009-07. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01009502?
The interventions under investigation include: sodium stibogluconate (DRUG).
Who is sponsoring clinical trial NCT01009502?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01009502's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia